Bausch Health Cos Debt to Equity Ratio 2012-2026 | BHC
Current and historical debt to equity ratio values for Bausch Health Cos (BHC) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bausch Health Cos debt/equity for the three months ending March 31, 2026 was 54.68.
| Bausch Health Cos Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $25.58B | $-1.08B | -23.64 |
| 2025-12-31 | $25.99B | $0.38B | 68.94 |
| 2025-09-30 | $26.47B | $0.36B | 74.35 |
| 2025-06-30 | $27.12B | $0.15B | 184.48 |
| 2025-03-31 | $26.66B | $-0.24B | -111.09 |
| 2024-12-31 | $26.85B | $-0.32B | -83.37 |
| 2024-09-30 | $26.78B | $-0.24B | -110.67 |
| 2024-06-30 | $26.72B | $-0.23B | -117.72 |
| 2024-03-31 | $27.09B | $-0.17B | -155.67 |
| 2023-12-31 | $27.43B | $-0.08B | -334.54 |
| 2023-09-30 | $27.30B | $-0.24B | -116.17 |
| 2023-06-30 | $25.23B | $0.27B | 93.11 |
| 2023-03-31 | $25.30B | $0.15B | 174.48 |
| 2022-12-31 | $25.43B | $0.26B | 97.79 |
| 2022-09-30 | $25.87B | $0.43B | 59.73 |
| 2022-06-30 | $27.92B | $0.25B | 110.35 |
| 2022-03-31 | $29.23B | $-0.14B | -207.31 |
| 2021-12-31 | $29.24B | $-0.03B | -859.88 |
| 2021-09-30 | $29.39B | $-0.14B | -217.68 |
| 2021-06-30 | $30.65B | $-0.61B | -50.17 |
| 2021-03-31 | $30.32B | $-0.12B | -244.52 |
| 2020-12-31 | $30.59B | $0.61B | 50.57 |
| 2020-09-30 | $30.91B | $0.66B | 47.19 |
| 2020-06-30 | $30.85B | $0.55B | 56.50 |
| 2020-03-31 | $31.08B | $0.79B | 39.34 |
| 2019-12-31 | $32.73B | $1.14B | 28.81 |
| 2019-09-30 | $29.11B | $2.56B | 11.37 |
| 2019-06-30 | $29.67B | $2.69B | 11.04 |
| 2019-03-31 | $29.77B | $2.78B | 10.71 |
| 2018-12-31 | $29.68B | $2.82B | 10.54 |
| 2018-09-30 | $30.54B | $3.24B | 9.44 |
| 2018-06-30 | $30.89B | $3.56B | 8.68 |
| 2018-03-31 | $31.28B | $4.52B | 6.92 |
| 2017-12-31 | $31.55B | $5.94B | 5.31 |
| 2017-09-30 | $34.55B | $5.42B | 6.37 |
| 2017-06-30 | $37.70B | $4.03B | 9.36 |
| 2017-03-31 | $38.34B | $3.99B | 9.60 |
| 2016-12-31 | $40.27B | $3.26B | 12.36 |
| 2016-09-30 | $41.49B | $4.27B | 9.71 |
| 2016-06-30 | $42.26B | $5.40B | 7.82 |
| 2016-03-31 | $43.24B | $5.78B | 7.49 |
| 2015-12-31 | $42.94B | $6.03B | 7.12 |
| 2015-09-30 | $41.99B | $6.47B | 6.50 |
| 2015-06-30 | $41.79B | $6.56B | 6.37 |
| 2015-03-31 | $31.99B | $6.58B | 4.87 |
| 2014-12-31 | $20.90B | $5.40B | 3.87 |
| 2014-09-30 | $21.83B | $5.23B | 4.17 |
| 2014-06-30 | $22.53B | $5.37B | 4.20 |
| 2014-03-31 | $22.79B | $5.20B | 4.38 |
| 2013-12-31 | $22.74B | $5.23B | 4.35 |
| 2013-09-30 | $23.14B | $5.06B | 4.57 |
| 2013-06-30 | $14.08B | $5.70B | 2.47 |
| 2013-03-31 | $13.90B | $3.59B | 3.88 |
| 2012-12-31 | $14.23B | $3.72B | 3.83 |
| 2012-09-30 | $10.36B | $3.79B | 2.74 |
| 2012-06-30 | $10.32B | $3.70B | 2.79 |
| 2012-03-31 | $9.54B | $4.08B | 2.34 |
| 2011-12-31 | $9.18B | $3.93B | 2.34 |
| 2011-09-30 | $7.80B | $4.01B | 1.94 |
| 2011-06-30 | $7.16B | $4.67B | 1.54 |
| 2011-03-31 | $6.98B | $4.71B | 1.48 |
| 2010-12-31 | $5.88B | $4.91B | 1.20 |
| 2010-09-30 | $5.79B | $5.35B | 1.08 |
| 2010-06-30 | $0.67B | $1.36B | 0.49 |
| 2010-03-31 | $0.66B | $1.34B | 0.49 |
| 2009-12-31 | $0.71B | $1.35B | 0.52 |
| 2009-09-30 | $0.73B | $1.29B | 0.57 |
| 2009-06-30 | $0.80B | $1.25B | 0.64 |
| 2009-03-31 | $0.38B | $1.18B | 0.32 |
| 2008-12-31 | $0.42B | $1.20B | 0.35 |
| 2008-09-30 | $0.34B | $1.16B | 0.29 |
| 2008-06-30 | $0.46B | $1.18B | 0.39 |
| 2008-03-31 | $0.50B | $1.29B | 0.39 |
| 2007-12-31 | $0.48B | $1.30B | 0.37 |
| 2007-09-30 | $0.33B | $1.38B | 0.24 |
| 2007-06-30 | $0.38B | $1.38B | 0.28 |
| 2007-03-31 | $0.85B | $1.34B | 0.63 |
| 2006-12-31 | $0.89B | $1.29B | 0.69 |
| 2006-09-30 | $0.80B | $1.27B | 0.63 |
| 2006-06-30 | $0.76B | $1.35B | 0.56 |
| 2006-03-31 | $0.78B | $1.28B | 0.61 |
| 2005-12-31 | $0.81B | $1.22B | 0.66 |
| 2005-09-30 | $0.73B | $1.18B | 0.62 |
| 2005-06-30 | $0.76B | $1.32B | 0.57 |
| 2005-03-31 | $0.65B | $1.06B | 0.61 |
| 2004-12-31 | $0.66B | $1.05B | 0.62 |
| 2004-09-30 | $0.77B | $1.00B | 0.78 |
| 2004-06-30 | $0.83B | $0.94B | 0.88 |
| 2004-03-31 | $0.92B | $0.91B | 1.01 |
| 2003-12-31 | $1.04B | $0.88B | 1.18 |
| 2003-09-30 | $1.07B | $0.96B | 1.12 |
| 2003-06-30 | $1.09B | $0.94B | 1.15 |
| 2003-03-31 | $0.86B | $0.92B | 0.94 |
| 2002-12-31 | $0.99B | $0.85B | 1.17 |
| 2002-09-30 | $0.73B | $0.93B | 0.79 |
| 2002-06-30 | $0.75B | $0.79B | 0.94 |
| 2002-03-31 | $0.62B | $0.92B | 0.67 |
| 2001-12-31 | $0.21B | $1.13B | 0.18 |
| 2001-09-30 | $0.59B | $0.45B | 1.30 |
| 2001-06-30 | $0.47B | $0.90B | 0.53 |
| 2001-03-31 | $0.75B | $0.27B | 2.75 |
| 2000-12-31 | $0.62B | $0.84B | 0.74 |
| 2000-09-30 | $0.37B | $0.28B | 1.31 |
| 2000-06-30 | $0.37B | $0.39B | 0.96 |
| 2000-03-31 | $0.37B | $0.36B | 1.01 |
| 1999-12-31 | $0.20B | $0.44B | 0.46 |
| 1999-09-30 | $0.17B | $0.06B | 2.73 |
| 1999-06-30 | $0.16B | $0.05B | 3.01 |
| 1999-03-31 | $0.16B | $0.05B | 3.35 |
| 1998-12-31 | $0.15B | $0.05B | 2.91 |
| 1998-09-30 | $0.04B | $0.09B | 0.51 |
| 1998-06-30 | $0.03B | $0.10B | 0.31 |
| 1998-03-31 | $0.04B | $0.09B | 0.43 |
| 1997-12-31 | $0.00B | 0.00 | |
| 1997-09-30 | $0.00B | 0.00 | |
| 1997-06-30 | $0.03B | $0.05B | 0.52 |
| 1997-03-31 | $0.02B | $0.04B | 0.53 |
| 1996-12-31 | $0.02B | $0.04B | 0.59 |
| 1996-09-30 | $0.04B | $0.03B | 1.16 |
| 1996-06-30 | $0.04B | $0.02B | 1.74 |
| 1996-03-31 | $0.00B | 0.00 | |
| 1995-12-31 | $0.05B | $0.02B | 3.17 |
| 1995-09-30 | $0.00B | 0.00 | |
| 1995-06-30 | $0.00B | 0.00 | |
| 1995-03-31 | $0.00B | 0.00 | |
| 1994-12-31 | $0.02B | $0.01B | 2.33 |
| 1994-09-30 | $0.00B | 0.00 | |
| 1994-06-30 | $0.02B | $0.01B | 4.11 |
| 1994-03-31 | $0.00B | 0.00 | |
| 1993-12-31 | $0.04B | $-0.01B | -5.88 |
| 1993-09-30 | $0.02B | $0.01B | 3.02 |
| 1992-12-31 | $0.04B | $-0.01B | -3.94 |
| 1991-12-31 | $0.00B | $0.00B | 0.00 |
| 1991-03-31 | $0.00B | $0.00B | 0.00 |
| 1990-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |